Answers are grounded in this paper and cite their sources.
Retrospective analysis reveals treatment disparities in HR+/HER2– metastatic breast cancer among U.S. women, indicating access gaps.
Background: Various factors such as race/ethnicity, practice settings, socioeconomic status (SES), and geographic region influence cancer outcomes. We describe treatment patterns and outcomes among women with HR+/HER2– metastatic breast cancer treated in the United States based on these factors. Methods: A retrospective, observational cohort study was conducted using the Flatiron Health Research Database of de-identified electronic health records in women ≥18 years in the United States who received first-line treatment for HR+/HER2– metastatic breast cancer from 1/1/2015-2/28/2023. Real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) were assessed using Kaplan-Meier methods. Results: The analysis included 6,974 women, who were most commonly non-Hispanic White (64%), lived in the South (37%), and received treatment in community settings (83%). From 2015-2019, the early uptake period of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), non-Hispanic White women were more likely to receive endocrine therapy (ET)+CDK4/6i versus non-Hispanic Black and Hispanic/Latino women; ET+CDK4/6i was less common in lower (Q1-Q3) versus higher (Q4-Q5) SES quintiles and in community versus academic settings. These differences were less pronounced from 2020-2023. Non-Hispanic White women had significantly longer rwOS versus non-Hispanic Black women, but shorter rwOS versus Hispanic/Latino women. RwOS was longer in academic versus community settings. No substantial differences in rwTTNTD were observed. Conclusions: We observed disparities in first-line treatment and outcomes among women with HR+/HER2– metastatic breast cancer during a time of changes to standard-of-care across racial/ethnic groups and practice settings. Impact: These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.
No takes yet. Share an insight, caveat, or question.
Vidal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: